Oxidative Stress in Structural Valve Deterioration: A Longitudinal Clinical Study
Manuel Galiñanes,
Kelly Casós,
Arnau Blasco-Lucas,
Eduard Permanyer,
Rafael Máñez,
Thierry Le Tourneau,
Jordi Barquinero,
Simo Schwartz,
Tomaso Bottio,
Jean Christian Roussel,
Imen Fellah-Hebia,
Thomas Sénage,
Arturo Evangelista,
Luigi P. Badano,
Alejandro Ruiz-Majoral,
Cesare Galli,
Vered Padler-Karavani,
Jean-Paul Soulillou,
Xavier Vidal,
Emanuele Cozzi,
Cristina Costa
Affiliations
Manuel Galiñanes
Reparative Therapy of the Heart, Vall d’Hebron Research Institute (VHIR), Passeig Vall d’Hebron, 119, Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain
Kelly Casós
Reparative Therapy of the Heart, Vall d’Hebron Research Institute (VHIR), Passeig Vall d’Hebron, 119, Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain
Arnau Blasco-Lucas
Reparative Therapy of the Heart, Vall d’Hebron Research Institute (VHIR), Passeig Vall d’Hebron, 119, Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain
Eduard Permanyer
Reparative Therapy of the Heart, Vall d’Hebron Research Institute (VHIR), Passeig Vall d’Hebron, 119, Autonomous University of Barcelona (UAB), 08035 Barcelona, Spain
Rafael Máñez
Infectious Diseases and Transplantation Division, Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital-ICS, 08908 Barcelona, Spain
Thierry Le Tourneau
CHU de Nantes, Institut du Thorax, Université de Nantes, CIC 1413, 44000 Nantes, France
Jordi Barquinero
Gene and Cell Therapy, VHIR, UAB, 08035 Barcelona, Spain
Simo Schwartz
Group of Drug Delivery and Targeting, Clinical Biochemistry Department, Vall d`Hebron Hospital Barcelona Campus, Vall d’Hebron Research Institute (VHIR), 08035 Barcelona, Spain
Tomaso Bottio
Department of Cardio Thorac Vascular Sciences and Public Health, Padua University Hospital, 35128 Padua, Italy
Jean Christian Roussel
Department of Thoracic and Cardiovascular Surgery, Institut du Thorax, University Hospital, 44007 Nantes, France
Imen Fellah-Hebia
CHU de Nantes, Institut du Thorax, Université de Nantes, CIC 1413, 44000 Nantes, France
Thomas Sénage
CHU de Nantes, Institut du Thorax, Université de Nantes, CIC 1413, 44000 Nantes, France
Arturo Evangelista
Department of Cardiology, Vall d’Hebron Research Institut (VHIR), Hospital Vall d’Hebron, 08035 Barcelona, Spain
Luigi P. Badano
Department of Medicine and Surgery, University of Milano-Bicocca, 20126 Milan, Italy
Alejandro Ruiz-Majoral
Department of Cardiology, Bellvitge University Hospital, 08907 Barcelona, Spain
Cesare Galli
Avantea and Fondazione Avantea Onlus, 26100 Cremona, Italy
Vered Padler-Karavani
Department of Cell Research and Immunology, The Shmunis School of Biomedicine and Cancer Research, The George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv 69978, Israel
Jean-Paul Soulillou
Institut de Transplantation–Urologie–Néphrologie, INSERM Unité Mixte de Recherche 1064, Centre Hospitalier Universitaire de Nantes, 44093 Nantes, France
Xavier Vidal
Department of Clinical Pharmacology, HUGH-ICS, 08001 Barcelona, Spain
Emanuele Cozzi
Transplant Immunology Unit, Department of Transfusion Medicine, Padua University Hospital, 35128 Padua, Italy
Cristina Costa
Infectious Diseases and Transplantation Division, Bellvitge Biomedical Research Institute (IDIBELL) and Bellvitge University Hospital-ICS, 08908 Barcelona, Spain
The cause of structural valve deterioration (SVD) is unclear. Therefore, we investigated oxidative stress markers in sera from patients with bioprosthetic heart valves (BHVs) and their association with SVD. Blood samples were taken from SVD (Phase A) and BHV patients during the first 24 (Phase B1) and >48 months (Phase B2) after BHV implantation to assess total antioxidant capacity (TAC), malondialdehyde (MDA), and nitrotyrosine (NT). The results show that MDA levels increased significantly 1 month after surgery in all groups but were higher at 6 months only in incipient SVD patients. NT levels increased gradually for the first 24 months after implantation in the BHV group. Patients with transcatheter aortic valve implantation (TAVI) showed even higher levels of stress markers. After >48 months, MDA and NT continued to increase in BHV patients with a further elevation after 60–72 months; however, these levels were significantly lower in the incipient and established SVD groups. In conclusion, oxidative stress may play a significant role in SVD, increasing early after BHV implantation, especially in TAVI cases, and also after 48 months’ follow-up, but decreasing when SVD develops. Oxidative stress potentially represents a target of therapeutic intervention and a biomarker of BHV dysfunction.